In an era of rapid sci­en­tif­ic ad­vance­ment and on­go­ing glob­al health chal­lenges, Gilead Sci­ences is ad­vanc­ing a long-term re­search strat­e­gy fo­cused on ar­eas of sig­nif­i­cant un­met med­ical need. In 2019, with a clear mis­sion to tack­le se­ri­ous dis­eases, Gilead out­lined a long-term plan to ad­vance 10 po­ten­tial trans­for­ma­tive ther­a­pies by 2030. This plan re­flects Gilead’s tar­get­ed in­vest­ments across HIV, on­col­o­gy, and in­flam­ma­to­ry dis­eases, un­der­scor­ing a fo­cus on re­search-dri­ven in­no­va­tion, strate­gic growth and glob­al col­lab­o­ra­tion.

For decades, Gilead has been syn­ony­mous with HIV treat­ment and pre­ven­tion lead­er­ship, es­tab­lish­ing it­self as a pi­o­neer in an­tivi­ral ther­a­py. This lega­cy con­tin­ues with com­pre­hen­sive re­search pro­grams that can lead to ground­break­ing ther­a­pies to help ad­dress the per­sis­tent chal­lenges of the glob­al HIV epi­dem­ic.

The re­cent U.S. ap­proval of the world’s first twice-year­ly HIV pre­ven­tion med­ica­tion adds an in­no­v­a­tive op­tion for those who need them most. In 2025, Gilead sub­mit­ted reg­u­la­to­ry fil­ing in 18 coun­tries rep­re­sent­ing a sub­stan­tial share of the glob­al HIV bur­den, with the goal of en­abling ini­tial ac­cess in re­source-lim­it­ed coun­tries, pend­ing reg­u­la­to­ry re­view and lo­cal ap­provals.

Build­ing on this break­through, Gilead­'s clin­i­cal HIV de­vel­op­ment pro­grams con­tin­ue to push bound­aries. These tri­als ex­plore in­no­v­a­tive ap­proach­es aimed at mak­ing HIV pre­ven­tion and treat­ment sim­pler, more ef­fec­tive and more ac­ces­si­ble for a broad va­ri­ety of peo­ple. Gilead stud­ies in­ves­ti­gate nov­el com­bi­na­tions, for­mu­la­tions, dos­ing strate­gies and de­liv­ery meth­ods that could fur­ther trans­form the HIV land­scape, re­in­forc­ing Gilead­'s com­mit­ment to help end HIV trans­mis­sion and im­prove out­comes for peo­ple world­wide.

Be­yond vi­rol­o­gy lead­er­ship, Gilead is build­ing the fu­ture of on­col­o­gy, in­flam­ma­tion and oth­er dis­ease ar­eas through tar­get­ed in­vest­ments in in­no­v­a­tive plat­forms and strate­gic ac­qui­si­tions. The com­pa­ny's on­col­o­gy strat­e­gy ad­dress­es the most ag­gres­sive, treat­ment-re­sis­tant can­cers, in­clud­ing breast, brain and rare blood can­cers.

In the rapid­ly evolv­ing field of cell ther­a­py, Gilead is dri­ving in­no­va­tion with its CAR-T can­di­dates. KITE-753, cur­rent­ly in Phase 1 stud­ies for lym­phoma, is ex­pect­ed to en­ter piv­otal stud­ies in 2026, while KITE-363 is be­ing eval­u­at­ed in Phase 1 stud­ies for re­frac­to­ry au­toim­mune dis­eases. Both can­di­dates uti­lize the KITE Duo­Core™ con­struct, an in­ves­ti­ga­tion­al de­sign that in­cor­po­rates two in­de­pen­dent CARs in­tend­ed to ad­dress chal­lenges such as anti­gen loss. On­go­ing stud­ies are ex­am­in­ing how this ap­proach may in­flu­ence dura­bil­i­ty of re­sponse, safe­ty pro­file, and treat­ment de­liv­ery set­tings. Ad­di­tion­al re­search will be re­quired to de­ter­mine how these at­trib­ut­es may trans­late in­to clin­i­cal prac­tice. Ad­di­tion­al­ly, KITE-753 lever­ages a nov­el man­u­fac­tur­ing process that pre­serves T-cell fit­ness. Com­bined, these de­vel­op­ments are tar­get­ed to pro­vide high­er ef­fi­ca­cy, low­er tox­i­c­i­ty, durable func­tion and faster de­liv­ery to pa­tients.

In the in­flam­ma­tion space, Gilead is tack­ling chron­ic dis­eases that cause life­long pain and dis­abil­i­ty, dras­ti­cal­ly im­pact­ing qual­i­ty of life for mil­lions of pa­tients world­wide. The com­pa­ny's re­search fo­cus­es on de­vel­op­ing nov­el ther­a­pies that tar­get un­der­ly­ing dis­ease mech­a­nisms rather than sim­ply man­ag­ing symp­toms, of­fer­ing the po­ten­tial for dis­ease mod­i­fi­ca­tion and im­proved long-term out­comes.

These di­verse pro­grams re­flect a dis­ci­plined, in­no­va­tion-dri­ven strat­e­gy, one that care­ful­ly bal­ances sci­en­tif­ic am­bi­tion with a laser fo­cus on de­liv­er­ing mean­ing­ful pa­tient out­comes and ad­dress­ing sig­nif­i­cant un­met med­ical needs.

Sci­en­tif­ic in­no­va­tion alone can­not ad­dress glob­al health chal­lenges with­out de­lib­er­ate, sys­tem-lev­el ac­cess plan­ning. Gilead has long em­bed­ded ac­cess con­sid­er­a­tions across its port­fo­lio, work­ing to en­sure that ad­vances in vi­rol­o­gy, on­col­o­gy, and in­flam­ma­to­ry dis­eases can reach pa­tients in di­verse health­care set­tings around the world. This ap­proach re­flects a be­lief that ac­cess must be de­signed along­side in­no­va­tion, tak­ing in­to ac­count af­ford­abil­i­ty, in­fra­struc­ture, reg­u­la­to­ry path­ways, and health­care ca­pac­i­ty.

One re­cent ex­am­ple of this ap­proach is Gilead’s work to ex­pand ac­cess to its long-act­ing HIV pre­ven­tion med­ica­tion. In 2024, the com­pa­ny signed roy­al­ty-free vol­un­tary li­cens­es with six gener­ic man­u­fac­tur­ers to make and sell the first twice year­ly treat­ment for HIV pre­ven­tion in 120 low- and low­er-mid­dle-in­come coun­tries. Gilead al­so com­plet­ed ear­ly tech­nol­o­gy trans­fers to sup­port man­u­fac­tur­ing readi­ness, rec­og­niz­ing that time­ly ac­cess re­quires prepa­ra­tion well in ad­vance of reg­u­la­to­ry re­view and lo­cal ap­provals.

Build­ing on its broad­er ac­cess frame­work, Gilead part­ners with glob­al health or­ga­ni­za­tions, gov­ern­ments, and non-prof­its to sup­port ac­cess across its port­fo­lio. This in­cludes col­lab­o­ra­tions with ini­tia­tives such as the U.S. State De­part­ment’s PEP­FAR pro­gram and the Glob­al Fund, which bring to­geth­er com­ple­men­tary ex­per­tise in pro­cure­ment, health sys­tem sup­port, and de­liv­ery. These part­ner­ships are de­signed to help en­sure that sci­en­tif­ic ad­vances across dis­ease ar­eas can trans­late in­to re­al-world im­pact.

Through strate­gic health­care in­sti­tu­tion part­ner­ships world­wide, Gilead helps de­vel­op com­pre­hen­sive screen­ing, test­ing and di­ag­nos­tic pro­to­cols for crit­i­cal vi­ral dis­eases. These col­lab­o­ra­tions ex­tend be­yond drug dis­tri­b­u­tion, en­com­pass­ing ca­pac­i­ty build­ing, health­care work­er train­ing and sup­port for in­fra­struc­ture de­vel­op­ment. By strength­en­ing health­care sys­tems, these part­ner­ships aim to help en­sure that break­through ther­a­pies can be ef­fec­tive­ly de­liv­ered to un­der­served pop­u­la­tions, trans­lat­ing in­no­va­tion in­to re­al-world im­pact.

This com­pre­hen­sive ap­proach re­flects a broad­er phi­los­o­phy deeply em­bed­ded in Gilead­'s cor­po­rate cul­ture: health­care in­no­va­tion must be in­clu­sive, sus­tain­able and glob­al­ly rel­e­vant to tru­ly trans­form pa­tient out­comes.

Look­ing ahead, Gilead­'s strat­e­gy is to con­tin­ue ac­cel­er­at­ing in­no­va­tion while main­tain­ing dis­ci­plined growth and re­source al­lo­ca­tion. By fo­cus­ing on trans­for­ma­tive ther­a­pies, strength­en­ing strate­gic health­care ecosys­tem col­lab­o­ra­tions, and dri­ving sus­tain­able stake­hold­er val­ue, Gilead aims to help shape the next era of bio­phar­ma­ceu­ti­cal in­no­va­tion.